StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis
- Conditions
- TuberculosisPulmonary Tuberculosis
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2023-09-18
- Target Recruit Count
- 16
- Registration Number
- NCT03882177
- Locations
- 🇿🇦
PHRU Non-Network CRS, Johannesburg, Gauteng, South Africa
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
- Conditions
- Peanut AllergyMulti-food Allergy
- Interventions
- Drug: OmalizumabOther: Double-Blind Placebo-Controlled Food Challenge Based TreatmentDrug: Placebo for OmalizumabDrug: Multi-Allergen Oral ImmunotherapyDrug: Placebo for Multi-Allergen Oral Immunotherapy
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-10-30
- Target Recruit Count
- 471
- Registration Number
- NCT03881696
- Locations
- 🇺🇸
Massachusetts General Hospital, Department of Medicine: Allergy & Clinical Immunology Unit, Boston, Massachusetts, United States
🇺🇸Emory University School of Medicine: Children's Healthcare of Atlanta Pediatrics, Atlanta, Georgia, United States
🇺🇸Johns Hopkins Children's Center: Department of Allergy & Immunology, Baltimore, Maryland, United States
VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
- Conditions
- Venezuelan Equine EncephalitisAlphavirus InfectionsWestern Equine EncephalitisEastern Equine Encephalitis
- Interventions
- Biological: VRC-WEVVLP073-00-VPOther: VRC-GENMIX083-AL-VP
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2021-03-24
- Target Recruit Count
- 30
- Registration Number
- NCT03879603
- Locations
- 🇺🇸
The Hope Clinic of the Emory Vaccine Center, Decatur, Georgia, United States
Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- Biological: Ad4-Env150KNBiological: Ad4-Env145NFLBiological: VRC-HIVRGP096-00-VP (Trimer 4571) with alum
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2025-01-09
- Target Recruit Count
- 300
- Registration Number
- NCT03878121
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells
- Conditions
- HIV Infections
- Interventions
- Biological: Stable CH505TF gp120Biological: Transient CH505TF gp120Biological: Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2024-07-12
- Target Recruit Count
- 30
- Registration Number
- NCT03856996
- Locations
- 🇺🇸
The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
🇺🇸Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
🇺🇸Vanderbilt Vaccine (VV) CRS, Nashville, Tennessee, United States
Clinical Study of a Diagnostic Device for NG, TV and CT in Women
- Conditions
- Chlamydial InfectionGonococcal InfectionTrichomoniasis
- Interventions
- Device: Click Device
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2022-01-13
- Target Recruit Count
- 1585
- Registration Number
- NCT03852316
- Locations
- 🇺🇸
University of Mississippi - Infectious Diseases, Jackson, Mississippi, United States
🇺🇸Axis Clinical Trials, Los Angeles, California, United States
🇺🇸South Florida Clinical Trials, Hialeah, Florida, United States
Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route
- Conditions
- Influenza
- Interventions
- Biological: Flucelvax(R)Other: Human Challenge virus
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2020-11-10
- Target Recruit Count
- 82
- Registration Number
- NCT03845231
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Experimental Human Infection With Neisseria Gonorrhoeae
- Conditions
- Gonococcal Infection
- Interventions
- Drug: CefiximeDrug: CeftriaxoneDrug: CiprofloxacinBiological: Neisseria gonorrhoeae strain FA7537Biological: Neisseria gonorrhoeae strain FA1090 A26
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2021-03-23
- Target Recruit Count
- 27
- Registration Number
- NCT03840811
- Locations
- 🇺🇸
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States
Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis
- Conditions
- Milk and/or Peanut Allergy
- Interventions
- Other: Dry Milk Powder and Corn Starch (placebo for Milk powder)Other: Peanut powder and Oat flourOther: Baked milk and Rice milk (placebo for Baked milk)Other: Peanut flour and Oat flour (placebo for peanut flour)
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2024-10-03
- Target Recruit Count
- 200
- Registration Number
- NCT03835767
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions
- Conditions
- HIV
- Interventions
- Biological: VRC-HIVMAB060-00-AB (VRC01)Biological: Normal Saline PlaceboBiological: 10-1074
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2021-10-12
- Target Recruit Count
- 27
- Registration Number
- NCT03831945
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States